Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H.sub.4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H.sub.4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.